KPV 10mg 10mL Vial
£295.00
MOA
- Anti-Inflammatory and Immune Regulation:
- KPV (Lys-Pro-Val) is a naturally occurring tripeptide derived from the C-terminal sequence of α-melanocyte–stimulating hormone (α-MSH). It exerts potent anti-inflammatory effects primarily through inhibition of NF-κB signaling, resulting in reduced expression of pro-inflammatory cytokines such as TNF-α and IL-6.
- MC1R Receptor Activation:
- KPV binds to melanocortin-1 receptors (MC1R) expressed on epithelial and immune cells, initiating cAMP-dependent signaling cascades that suppress inflammatory mediator release and promote cellular resilience. This receptor-mediated mechanism contributes to immunomodulation and protection against chronic inflammation.
- Epithelial Barrier Integrity:
- KPV enhances epithelial barrier function by strengthening tight junction proteins and promoting mucosal repair. These effects are especially relevant in gastrointestinal and dermatologic tissues, where barrier disruption contributes to inflammation and immune dysregulation.
- Antimicrobial and Cytoprotective Effects:
- In addition to its anti-inflammatory actions, KPV exhibits broad-spectrum antimicrobial activity across skin and gut tissues. This antimicrobial property, combined with its ability to stabilize epithelial integrity, supports host defense and tissue recovery under inflammatory or infectious stress.
- Systemic and Localized Therapeutic Potential:
- Through its combined roles in immune regulation, epithelial protection, and microbial balance, KPV offers dual systemic and localized benefits in conditions characterized by inflammation, barrier dysfunction, or immune activation.
More Information
- Disclaimer: For Research Purposes Only – All products on this site are for Research and Development use only. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease. Celia Health is a supplier of research-use chemicals manufactured in a CGMP facility in the US. Celia Health is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act.
